Hair Growth Claim Substantiation: TrichoScan, Phototrichogram & Hair Tensile Test

Overview #

Hair growth claims are not marketing language. They are regulatory commitments that require documented, reproducible evidence — and the method you choose to generate that evidence shapes everything from your formulation brief to your packaging copy. When brand partners come to us with a “stimulates hair growth” brief, the first question we ask is: what claim level are you targeting, and what market are you selling into? The answer determines whether we’re designing around a TrichoScan protocol, a phototrichogram endpoint, or a tensile strength panel — and those are not interchangeable.

What the Claim Actually Commits You To #

“Promotes hair growth” sounds straightforward. It isn’t. Under EU Cosmetics Regulation 1223/2009, any claim must be substantiated by evidence proportionate to the claim’s strength. “Visibly fuller-looking hair” sits in a different evidentiary tier than “increases hair density by X%.” We see brands conflate these constantly, and it’s usually where the project scope doubles unexpectedly.

The three methods we work with most — TrichoScan, phototrichogram, and hair tensile testing — each answer a different question. TrichoScan gives you density and anagen/telogen ratio from digital dermoscopy images, typically analyzed at a standardized scalp zone (usually 1.8 cm² at the vertex or temporal region). Phototrichogram is the older, more manual method: you clip a defined area, photograph at day 0 and day 3, and count regrowth to classify follicle cycling status. Tensile testing measures something else entirely — fiber mechanical properties, not follicle biology. Specifically, we’re looking at break force (typically 40–120 gN range for healthy Caucasian hair), elongation at break, and Young’s modulus.

Brands often brief us wanting all three. Honestly, that’s usually overkill, and it adds 8–12 weeks to the development timeline plus significant cost. We almost always push back and ask: what’s the primary claim, and what’s the supporting claim?

Choosing the Right Test Method for Your Brief #

Here’s how we frame the decision internally. TrichoScan is the gold standard for density and cycling claims. A well-run TrichoScan study — 60 subjects, 24 weeks, standardized photography protocol — can support “increases hair density by X%” with the kind of numerical precision that survives EU regulatory scrutiny. The limitation is cost and timeline. A properly powered study runs 18–24 weeks minimum if you want statistically meaningful anagen rate data.

Phototrichogram is faster and cheaper, but the inter-rater variability is real. In our experience coordinating with CRO partners, you need strict SOP alignment on clipping depth, photography angle, and image analysis software to get reproducible results across sites. We’ve seen studies where two analysts reviewing the same images disagreed on anagen/telogen classification by up to 12% — which is enough to flip a borderline result. That’s not a formulation problem. It’s a protocol problem. But it becomes your problem when the claim gets challenged.

Tensile testing is where we spend the most time on the formulation side, because it’s the one we can actually influence most directly in the lab. Fiber strength responds to surface treatment — film-forming polymers, ceramide analogues, hydrolyzed proteins at 0.5–2.0% active loading. We can move break force measurably within a single-use application in controlled conditions. The clinical translation is less clean, but for “strengthens hair” or “reduces breakage” claims, it’s the most defensible path.

One clinical reference we use internally as a benchmark: a double-blind, placebo-controlled study (n=60, 24 weeks) evaluating a standardized Redensyl® formulation at 3% in a leave-on scalp serum showed a 17% increase in anagen hair density versus baseline, with a 9% improvement versus placebo at week 24. The phototrichogram endpoint was the primary measure. What that study doesn’t tell you — and what we’ve learned from our own batches — is that the vehicle matters enormously. The same active at 3% in a high-alcohol toner versus a low-alcohol serum base gave us meaningfully different scalp penetration profiles in our Franz cell work.

For FDA Cosmetics Guidelines compliance in the US market, the boundary between cosmetic and drug claim is particularly sensitive for hair growth. “Regrows hair” is a drug claim. “Helps hair appear thicker” is cosmetic. We map every claim through this filter before we finalize the brief.

Development Tier Comparison: Mass Market vs. Premium vs. Clinical-Grade #

This is usually the most useful conversation we have at kickoff. The tier you’re targeting determines active selection, testing investment, and packaging spec — and the cost differences are significant.

A few things worth flagging on that table. The mass-market tier is not “less effective” — it’s a different claim architecture. Caffeine at 1.5% with a solid tensile test panel and a consumer perception study (“hair feels stronger after 4 weeks”) is a completely defensible commercial position. We’ve launched products in that tier that outperformed premium SKUs in repeat purchase. The premium tier is where most of our brand partners land, and where the formulation decisions get genuinely complex.

Airless pump packaging for a leave-on scalp serum adds roughly USD 0.40–0.80 per unit at MOQ 3,000. Most indie brands can’t absorb that at launch, so we often spec a standard disc-top or dropper for the first run and plan the packaging upgrade at reorder. It’s not ideal from a preservation standpoint — airless is better for oxidation-sensitive actives like Redensyl® — but it’s the commercial reality.

Where Most Brands Get the Formulation Wrong #

The brief usually says: “scalp serum, hair growth, clean formula, no silicones, fragrance-free.” Fine. But then the active list comes in and it’s Redensyl® at 3%, Capixyl™ at 1%, Procapil® at 3%, plus a peptide complex. That’s a high-load multi-active system, and the interaction effects are not always additive.

In our lab, we’ve seen pH sensitivity cause real problems here. Redensyl® is stable at pH 4.5–6.5. Capixyl™ — which is a peptide-lipid complex — starts showing hydrolysis above pH 6.0 in our accelerated stability work (40°C/75% RH, 12 weeks). If you’re trying to run both in the same base, you’re managing a narrow pH window. Drop below 4.5 and you’re potentially irritating a sensitized scalp. Go above 6.0 and you’re degrading one of your hero actives. We target pH 5.0–5.5 for these systems, buffered with citrate-phosphate.

The scale-up failure we see most often in this category: worked perfectly at 500g lab scale, gram-negative contamination appeared at week 10 of PCT when we moved to 150kg production. The root cause was the water activity in the base — slightly higher at production scale due to mixing dynamics — which pushed the preservative system below its effective threshold. We now require a full preservative efficacy test (ISO 11930) on the first production batch, not just the lab prototype. That adds 4 weeks to the timeline. Non-negotiable.

Honestly, most brands underestimate how much the scalp microbiome angle complicates preservation. If you’re making a “microbiome-friendly” claim alongside a hair growth claim, your preservative options narrow considerably. Phenoxyethanol at 0.8–1.0% is usually fine, but some of the more aggressive systems that would give you better broad-spectrum coverage are incompatible with a microbiome positioning. We’re still not fully convinced the clinical evidence for “microbiome-friendly” scalp products is strong enough to justify the formulation constraints in every case — but the market is asking for it, so we work within it. See our notes on microbiome and probiotic skincare formulation for how we handle this across categories.

Development Timeline: What to Expect #

A realistic timeline for a premium-tier scalp serum with phototrichogram substantiation:

Weeks 1–2: Brief alignment, active selection, regulatory mapping for target markets. Weeks 3–6: Prototype development, 3–5 formula iterations, initial stability screening. Weeks 7–10: Stability confirmation (accelerated, 40°C/75% RH), preservative efficacy testing, sensory panel. Weeks 11–14: Packaging compatibility testing, fill weight optimization, pilot batch at 20–50kg. Weeks 15–36: CRO clinical study (phototrichogram, n=40 minimum, 24-week protocol). Weeks 37–40: Claim copy finalization, regulatory dossier preparation, production batch.

That’s roughly 10 months from brief to launch-ready. Brands who come to us expecting 4 months are usually targeting a consumer perception panel only — which is a legitimate choice, but it’s a different product and a different claim.

For NMPA Cosmetic Regulation registration in China, hair growth claims trigger special cosmetic classification, which adds a separate regulatory pathway with its own efficacy testing requirements. We flag this early because it affects active selection — some ingredients approved under EU or FDA frameworks are not on the NMPA permitted list for special cosmetics.

For deeper context on how we approach active delivery in leave-on scalp formats, see our encapsulation technology formulation guide.

Formulation Notes for Brand Partners #

What market? What are you expecting on-pack? Those are the first two questions we ask in every kickoff. Not because we’re being difficult — because the answers determine everything downstream.

If you’re launching in the EU and want to say “clinically proven to increase hair density,” we need a TrichoScan or phototrichogram study with at least 40 subjects and a 16–24 week duration. That’s the evidentiary floor. If you’re launching DTC in the US with a “visibly thicker-looking hair” claim, a well-designed consumer use study (n=30, 8 weeks) with a tensile test panel gets you there faster and cheaper.

On actives: we have preferred supplier relationships for Redensyl®, Capixyl™, and Procapil®, and we’ve run enough batches to know which lots perform consistently. We don’t just take supplier efficacy data at face value — we run our own Franz cell penetration work on new lots when the active loading is above 1%. That’s added cost, but it’s caught batch-to-batch variation that would have compromised a clinical study.

Budget honestly with us at brief stage. A full clinical-grade development program with RCT substantiation is a different investment than a premium consumer product with perception panel support. Both are valid. We can build either. But we can’t build a clinical-grade product on a mass-market budget, and we’ve learned the hard way that trying to meet in the middle usually satisfies nobody.

Frequently Asked Questions #

Q: We want to claim “increases hair density by 17%” — what do we actually need to back that up?

You need a controlled clinical study with TrichoScan or phototrichogram as the primary endpoint, minimum n=40, run for at least 16 weeks, with a placebo or vehicle control arm. The 17% figure needs to be statistically significant (p<0.05) versus control, not just versus baseline. Budget roughly USD 35,000–60,000 for a properly powered CRO study at that spec.

Q: Can we use the ingredient supplier’s clinical data for our claim?

Sometimes, but it’s complicated. Supplier data substantiates the ingredient, not your finished formula. If your formula matches the study vehicle, concentration, and application protocol exactly, you have a reasonable basis. In practice, most formulas deviate enough that we recommend at least a bridging consumer study (n=20–30) to support the claim on your specific product.

Q: How long does a phototrichogram study take versus TrichoScan?

A phototrichogram study can be designed for 12–16 weeks with faster readouts at week 8. TrichoScan studies typically run 24 weeks for meaningful density data. The phototrichogram is faster and lower cost, but inter-rater variability is a real issue — you need a CRO with a validated image analysis protocol. We’ve seen 8-week phototrichogram studies used for “reduces hair loss” claims, which is a shorter timeline but a more limited claim scope.

Q: Our formula has Redensyl® at 3% and Procapil® at 3% — is that combination stable?

It can be, but the pH window is tight. We run these combinations at pH 5.0–5.5 with citrate-phosphate buffer and test at 40°C/75% RH for 12 weeks minimum. At that loading, you’re also looking at a higher-cost base — combined active cost alone is roughly USD 1.80–2.40 per 50ml unit before any other formulation costs.

Q: Do we need separate testing for the EU and US markets?

For the EU, your claim substantiation needs to align with the SCCS Scientific Opinion framework and EU cosmetic claims regulation. For the US, FDA doesn’t require pre-market approval for cosmetic claims, but the FTC holds you to substantiation standards. A well-designed clinical study generally satisfies both markets. Where it gets complicated is China — NMPA special cosmetic registration requires China-specific efficacy testing conducted at a NMPA-recognized institution, and foreign study data is not always accepted.

Have a product concept in mind? Contact our formulation team to request a complimentary brief review.